Market Place
Sourcing Support
Cassava Sciences Rebrands As Filana Therapeutics
10 Mar 2026 //
GLOBENEWSWIRE
Ensysce Biosciences Invited to Upcoming Scientific, Industry
23 Feb 2026 //
PHARMIWEB
Cassava Settles Securities Class Action Lawsuit
23 Dec 2025 //
GLOBENEWSWIRE
Lexicon Presents Pilavapadin Data in Peripheral Neuropathy
14 Oct 2025 //
GLOBENEWSWIRE
Cassava Presents Promising Simufilam Data at TSC Alliance Meeting
30 Jun 2025 //
GLOBENEWSWIRE
Cassava Reports Q1 2025 Financials and Business Update
08 May 2025 //
GLOBENEWSWIRE
Cassava Chief Medical Officer Retires, Dr. Jack Moore Appointed
21 Apr 2025 //
GLOBENEWSWIRE
Cassava Sciences to face lawsuit over Alzheimer`s drug
26 Mar 2025 //
REUTERS
Cassava controversial Alzheimer`s drug fails in 2nd stage study
26 Mar 2025 //
REUTERS
Cassava Reports FY24 Results & Business Update
03 Mar 2025 //
GLOBENEWSWIRE
Cassava Sciences Licenses Simufilam Method of Treatment Patent
27 Feb 2025 //
GLOBENEWSWIRE
Cassava cuts 3rd of staff in wake of phase 3 Alzheimer`s fail
08 Jan 2025 //
FIERCE BIOTECH
Cassava Sciences Appoints Freda as Chief Commercial Officer
18 Nov 2024 //
INVESTING
SEC charges Cassava over `misleading` Alzheimer`s claims
30 Sep 2024 //
PHARMAPHORUM
Cassava Agrees to Pay $40M Fine to Resolve SEC Probe
28 Sep 2024 //
FIERCE BIOTECH
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
05 Aug 2024 //
GLOBENEWSWIRE
Cassava Sciences Announces Expansion of Open-Label Extension Trials
30 Jul 2024 //
GLOBENEWSWIRE
Cassava Sciences Announces Leadership And Governance Changes
17 Jul 2024 //
GLOBENEWSWIRE
Cassava Sciences forms internal panel after US probe into two employees
01 Jul 2024 //
REUTERS
US professor charged with manipulating data for Alzheimer’s drug trial
29 Jun 2024 //
REUTERS
Cassava Sciences Issues Statement on Former Science Advisor
28 Jun 2024 //
GLOBENEWSWIRE
Cassava Sciences Q1 2024 Financials, Simufilam Phase 3 Updates
10 May 2024 //
GLOBENEWSWIRE
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
08 May 2024 //
GLOBENEWSWIRE
Redemption Date Announced For Warrants
15 Apr 2024 //
GLOBENEWSWIRE
Cassava Announces Completion of Safety Review of Oral Simufilam Pha 3 Trials
25 Mar 2024 //
GLOBENEWSWIRE
Cassava Sciences again under scrutiny over Alzheimer`s drug research
11 Mar 2024 //
PRESS RELEASE
Cassava Sciences Announces Virtual Presentation at the AD/PD
04 Mar 2024 //
GLOBENEWSWIRE
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
28 Feb 2024 //
GLOBENEWSWIRE
No Decline in Cognition Scores in Patients with Mild Alzheimer`s Disease
07 Feb 2024 //
GLOBENEWSWIRE
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
05 Jan 2024 //
GLOBENEWSWIRE
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
12 Dec 2023 //
GLOBENEWSWIRE
Cassava Sciences Appoints Three New Members to its Board of Directors
07 Dec 2023 //
GLOBENEWSWIRE
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
07 Nov 2023 //
GLOBENEWSWIRE
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam
06 Nov 2023 //
GLOBENEWSWIRE
Statement by Cassava Regarding an Internal CUNY Report Leaked to the Press
12 Oct 2023 //
GLOBENEWSWIRE
Cassava Completes Patient Enrollment for Phase 3 Trial of Oral Simufilam
02 Oct 2023 //
GLOBENEWSWIRE
Cassava Announces Positive Safety Review of Simufilam Phase 3 Trials
18 Sep 2023 //
GLOBENEWSWIRE
Cassava Announces Publication That Confirms Mechanism of Action of Simufilam
11 Sep 2023 //
GLOBENEWSWIRE
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
06 Sep 2023 //
GLOBENEWSWIRE
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
03 Aug 2023 //
GLOBENEWSWIRE
New Research Shows Simufilam Suppresses Overactive mTOR
27 Jun 2023 //
GLOBENEWSWIRE
New Publication Highlights Basic Science Supporting Simufilam
12 Jun 2023 //
GLOBENEWSWIRE
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Why Shares of Cassava Sciences Jumped This Week
12 May 2023 //
FOOL
Cassava doses all patients in trial of Alzheimer’s treatment
12 May 2023 //
CLINICAL TRIALS ARENA
Cassava Completes Patient Dosing in a Randomized Controlled Trial of Simufilam
11 May 2023 //
GLOBENEWSWIRE
New Data by Academic Researchers Highlights Biological Activity of Simufilam
08 May 2023 //
GLOBENEWSWIRE
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
01 May 2023 //
GLOBENEWSWIRE
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
26 Apr 2023 //
GLOBENEWSWIRE
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
28 Feb 2023 //
GLOBENEWSWIRE
SmileDirectClub Reports Fourth Quarter and Full Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Cassava Announces Patient Enrollment Update for Phase 3 Studies of Simufilam
08 Feb 2023 //
GLOBENEWSWIRE
Cassava claims win in open-label Alzheimer`s study, shares fall
24 Jan 2023 //
FIERCE BIOTECH
Cassava Sciences Announces Positive Results in PII Study Evaluating Simufilam
24 Jan 2023 //
GLOBENEWSWIRE
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann
20 Dec 2022 //
GLOBENEWSWIRE
Cassava Sciences Announces Completion of Dosing in Open-label of Simufilam for AD
06 Dec 2022 //
GLOBENEWSWIRE
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
22 Nov 2022 //
GLOBENEWSWIRE
Cassava Sciences down 9% following $50M registered direct offering
18 Nov 2022 //
SEEKING ALPHA
Cassava Sciences Announces $50 M Registered Direct Offering of Common Stock
18 Nov 2022 //
GLOBENEWSWIRE
Cassava Sciences Reports Third Quarter Financial Results for 2022
07 Nov 2022 //
GLOBENEWSWIRE
